Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. It has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
企業コードJUNS
会社名Jupiter Neurosciences Inc
上場日Dec 03, 2024
最高経営責任者「CEO」Mr. Christer Rosen
従業員数4
証券種類Ordinary Share
決算期末Dec 03
本社所在地1001 North US HWY 1, Suite 504
都市PALM BEACH GARDENS
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号33477
電話番号15614066154
ウェブサイトhttps://jupiterneurosciences.com/
企業コードJUNS
上場日Dec 03, 2024
最高経営責任者「CEO」Mr. Christer Rosen
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし